脂肪生成
吡格列酮
间充质干细胞
罗格列酮
代谢通量分析
代谢物
焊剂(冶金)
化学
曲格列酮
脂肪组织
药理学
生物
生物化学
过氧化物酶体
细胞生物学
新陈代谢
内分泌学
糖尿病
2型糖尿病
受体
有机化学
作者
Kristýna Brejchová,Michal Rahm,Andrea Beňová,Veronika Domanska,Paul Reyes-Gutierez,Martina Dzubanova,Radka Trubacova,Michaela Vondráčková,Tomáš Čajka,Michaela Tencerová,Milan Vrábel,Ondřej Kuda
标识
DOI:10.1016/j.metabol.2025.156157
摘要
Highlights•MSDC-0602K differentially affects BM-MSCs and AT-MSCs.•Bioorthogonal click chemistry allowed measurement of pyruvate pools.•Subcellular metabolic flux analysis revealed rewiring of pyruvate pathways.•Metabolic flux analysis of TG synthesis showed distinct adipogenic strategies.AbstractObjectiveInsulin-sensitizing drugs, despite their broad use against type 2 diabetes, can adversely affect bone health, and the mechanisms underlying these side effects remain largely unclear. Here, we investigated the different metabolic effects of a series of thiazolidinediones, including rosiglitazone, pioglitazone, and the second-generation compound MSDC-0602 K, on human mesenchymal stem cells (MSCs).MethodsWe developed 13C subcellular metabolomic tracer analysis measuring separate mitochondrial and cytosolic metabolite pools, lipidomic network-based isotopologue models, and bioorthogonal click chemistry, to demonstrate that MSDC-0602 K differentially affected bone marrow-derived MSCs (BM-MSCs) and adipose tissue-derived MSCs (AT-MSCs). In BM-MSCs, MSDC-0602 K promoted osteoblastic differentiation and suppressed adipogenesis. This effect was clearly distinct from that of the earlier drugs and that on AT-MSCs.ResultsFluxomic data reveal unexpected differences between this drug's effect on MSCs and provide mechanistic insight into the pharmacologic inhibition of mitochondrial pyruvate carrier 1 (MPC). Our study demonstrates that MSDC-0602 K retains the capacity to inhibit MPC, akin to rosiglitazone but unlike pioglitazone, enabling the utilization of alternative metabolic pathways. Notably, MSDC-0602 K exhibits a limited lipogenic potential compared to both rosiglitazone and pioglitazone, each of which employs a distinct lipogenic strategy.ConclusionsThese findings indicate that the new-generation drugs do not compromise bone structure, offering a safer alternative for treating insulin resistance. Moreover, these results highlight the ability of cell compartment-specific metabolite labeling by click reactions and tracer metabolomics analysis of complex lipids to discover molecular mechanisms within the intersection of carbohydrate and lipid metabolism.Graphical abstract
科研通智能强力驱动
Strongly Powered by AbleSci AI